SHANGHAI, China, Jan. 23 /Xinhua-PRNewswire/ -- WuXi PharmaTech Recently announced the key appointment of Dr. Angela Wong as Vice President of Service Biology.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
Dr. Wong has board experiences in pharmacology, high throughput screening and preclinical pharmacokinetics. Prior to joining WuXi PharmaTech, she spent 20 years in pharmaceutical research at SmithKline, Pharmacopeia and Vitae Pharmaceuticals. She made significant contributions in multiple therapeutic areas including inflammation, cancer, hypertension, and osteoporosis. One of her compounds is currently in clinical trial for the treatment of asthma.
At her new post, Dr. Wong will be responsible for creating and managing Biology Service Group that provides services in the areas of drug metabolism, pharmacokinetics, toxicokinetics, immunoassay/biomarker, biological assay development and screening.
''I am very pleased to announce the appointment of such a highly accomplished professional to our management team. The addition of Dr. Wong to our scientific leadership broadens our service spectrum and enhances our capability. With her research experience and knowledge WuXi PharmaTech is one step closer to becoming an integrated R&D service provider,’' WuXi PharmaTech’s Chairman & CEO Dr. Ge Li said.
Dr. Wong received her Bachelor of Science Degree in Biochemistry in 1977 and Master of Philosophy Degree in Biochemistry in 1980 from Chinese University of Hong Kong, and Ph.D. in Pharmacology from Baylor College of Medicine in Texas, United States.
Founded in 2001 and located in WaiGaoQiao Free Trade Zone, Shanghai, WuXi PharmaTech is a research service company that provides services to support new drug discovery and the chemical development of new drug candidates from discovery through to market. It engages in chemistry research, from lead discovery, optimization, bioanalytical services, and development to commercial manufacturing.
Wuxi PharmaTech assists its partners to shorten the cycle and lower the cost of drug development by providing complete, cost-effective and rapid chemistry solutions. The competent management team consists of many experienced ''returnees’’ and is well-versed in the latest drug R&D methodologies and Western style business practices. With over 650 scientists, the company has a 300,000 sq. ft. state-of-the-art research center and a 250,000 sq. ft. GMP plant. The company’s current customers include 18 of the top 20 pharmaceutical companies and 8 of the top 10 biopharmaceutical companies in the world.
For more information, please contact: David Yin, PR Department, WuXi PharmaTech Co., Ltd. Tel: +86-21-5046-4003 Fax: +86-21-5046-1000 Email: Yin_Xiaojun@pharmatechs.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, +1-888-776-6555 or +1-212-782-2840WuXi PharmaTech Co., Ltd.
CONTACT: David Yin, PR Department of WuXi PharmaTech Co., Ltd.,+86-21-5046-4003, or fax, +86-21-5046-1000, or Yin_Xiaojun@pharmatechs.com
